ArticleMedicina (Kaunas, Lithuania)2022
Multiparametric MRI Features of Breast Cancer Molecular Subtypes.
Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Concordance of Digital Breast Tomosynthesis (DBT) and Magnetic Resonance Imaging (MRI) Measured Tumor Size with the Pathological Gold Standard: A Retrospective Cohort Analysis by Molecular Subtype and Breast Density.Diagnostics (Basel, Switzerland) · 2026Article
- A pilot study of multimodal MRI for the preoperative assessment of triple-negative breast cancer.Frontiers in oncology · 2026Article
- Evaluation of Diagnostic Accuracy of Combined Ultrasound Elastography and Magnetic Resonance Imaging in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Exploiting machine-learning models with DCE-MRI radiomics for breast cancer molecular subtyping.Frontiers in oncology · 2026Article
- Distinguishing Low Expression Levels of Human Epidermal Growth Factor Receptor 2 in Breast Cancer: Insights from Qualitative and Quantitative Magnetic Resonance Imaging Analysis.Tomography (Ann Arbor, Mich.) · 2025Article
- Correlation analysis of multiparametric magnetic resonance imaging features and molecular subtypes of breast cancer.Journal of clinical imaging science · 2025Article
- Predicting Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer Based on Radiomics of MRI Habitat and US.Breast cancer (Dove Medical Press) · 2025Article
- Preoperatively predicting human epidermal growth factor receptor 2-low expression in breast cancer using neural network model based on multiparameter magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2024Article
- HER-2 expression is correlated with multimodal imaging features in breast cancer: a pilot study.Annals of medicine · 2024Article
- The potential role of breast MRI in evaluation of triple-negative breast cancer and fibroadenoma of less than 3 cm.Translational cancer research · 2024Article
- Correlations of Imaging and Therapy in Breast Cancer Based on Molecular Patterns: An Important Issue in the Diagnosis of Breast Cancer.International journal of molecular sciences · 2024Review
- Histogram analysis comparison of readout-segmented and single-shot echo-planar imaging for differentiating luminal from non-luminal breast cancer.Scientific reports · 2024Article
- Clinical and Imaging Features of MRI Screen-Detected Breast Cancer.Clinical breast cancer · 2024Article
- Advances in Cancer Therapy from Research to Clinical Practice-Surgical, Molecular or Systemic Management of Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Whole-Tumor ADC Texture Analysis Is Able to Predict Breast Cancer Receptor Status.Diagnostics (Basel, Switzerland) · 2023Article
- Identification of Luminal A breast cancer by using deep learning analysis based on multi-modal images.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Breast cancer (BC) molecular subtypes have unique incidence, survival and response to therapy. There are five BC subtypes described by immunohistochemistry: luminal A, luminal B HER2 positive and HER2 negative, triple negative (TNBC) and HER2-enriched. Multiparametric breast MRI (magnetic resonance imaging) provides morphological and functional characteristics of breast tumours and is nowadays recommended in the preoperative setting. Aim: To evaluate the multiparametric MRI features (T2-WI, ADC values and DCE) of breast tumours along with breast density and background parenchymal enhancement (BPE) features among different BC molecular subtypes. Materials and Methods: This was a retrospective study which included 344 patients. All underwent multiparametric breast MRI (T2WI, ADC and DCE sequences) and features were extracted according to the latest BIRADS lexicon. The inter-reader agreement was assessed using the intraclass coefficient (ICC) between the ROI of ADC obtained from the two breast imagers (experienced and moderately experienced). Results: The study population was divided as follows: 89 (26%) with luminal A, 39 (11.5%) luminal B HER2 positive, 168 (48.5%) luminal B HER2 negative, 41 (12%) triple negative (TNBC) and 7 (2%) with HER2 enriched. Luminal A tumours were associated with special histology type, smallest tumour size and persistent kinetic curve (all p-values < 0.05). Luminal B HER2 negative tumours were associated with lowest ADC value (0.77 × 10−3 mm2/s2), which predicts the BC molecular subtype with an accuracy of 0.583. TNBC were associated with asymmetric and moderate/marked BPE, round/oval masses with circumscribed margins and rim enhancement (all p-values < 0.05). HER2 enriched BC were associated with the largest tumour size (mean 37.28 mm, p-value = 0.02). Conclusions: BC molecular subtypes can be associated with T2WI, ADC and DCE MRI features. ADC can help predict the luminal B HER2 negative cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.